Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025)

Prelude Therapeutics (PRLD) has disclosed Non-Current Deffered Revenue for 1 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.8 million for FY2025, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $1.8 million in Q4 2025 for Prelude Therapeutics.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.8 million in Q4 2025 to a low of $1.8 million in Q4 2025.